{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:53:58Z","timestamp":1790708038748,"version":"4.1.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.ejca.2004.12.023","type":"journal-article","created":{"date-parts":[[2005,2,8]],"date-time":"2005-02-08T10:15:25Z","timestamp":1107857725000},"page":"702-707","source":"Crossref","is-referenced-by-count":97,"title":["Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3weeks in solid tumours: An ECSG\/EORTC study"],"prefix":"10.1016","volume":"41","author":[{"given":"Alain","family":"Ravaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cerny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Terret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jantien","family":"Wanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binh Nguyen","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Droz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fumoleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Twelves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2004.12.023_bib1","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1016\/S0960-894X(97)10152-4","article-title":"Novel cyanoguanidines with potent oral antitumor activity","volume":"7","author":"Schou","year":"1997","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejca.2004.12.023_bib2","first-page":"5751","article-title":"CHS 828 a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo","volume":"59","author":"Hjarnaa","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2004.12.023_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-2999(01)00944-X","article-title":"Cellular pharmacodynamics of the cytotoxic guanidino-containing drug CHS828. Comparison with methylglyoxal-bis (guanylhdrazone)","volume":"418","author":"Ekelund","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ejca.2004.12.023_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0014-2999(01)00925-6","article-title":"Cell death with atypical features induced by the novel antitumoral drug CHS 828, i, human U-937 GTB cells","volume":"417","author":"Martinsson","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ejca.2004.12.023_bib5","first-page":"2843","article-title":"A phase I study of CHS 828 in patients with solid tumor malignancy","volume":"8","author":"Hovstadius","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2004.12.023_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002800000181","article-title":"Determination of drug effect on tumor cells, host animal toxicity and drug pharmacokinetics in a hallow-fibre model in rats","volume":"46","author":"Jonsson","year":"2000","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804905000237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804905000237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T16:51:13Z","timestamp":1548780673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804905000237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0959804905000237"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2004.12.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}